Literature DB >> 18326485

Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function.

Wei-Hua Shen1, Zhuang Chen, Shu Shi, Hanying Chen, Wuqiang Zhu, Anne Penner, Guixue Bu, Wei Li, David W Boyle, Michael Rubart, Loren J Field, Robert Abraham, Edward A Liechty, Weinian Shou.   

Abstract

Mammalian target of rapamycin (mTOR) is a key regulator for cell growth through modulating components of the translation machinery. Previously, numerous pharmacological studies using rapamycin suggested that mTOR has an important role in regulating cardiac hypertrophic growth. To further investigate this assumption, we have generated two lines of cardiac specific mTOR transgenic mice, kinase-dead (kd) mTOR and constitutively active (ca) mTOR, using alpha-myosin heavy chain promoter. alpha-Myosin heavy chain (alphaMHC)-mTORkd mice had a near complete inhibition of p70 S6k and 4E-BP1 phosphorylation, whereas alphaMHC-mTORca had a significant increase in p70 S6k and 4E-BP1 phosphorylation. Although the cardiac function of alphaMHC-mTORkd mice was significantly altered, the cardiac morphology of these transgenic mice was normal. The cardiac hypertrophic growth in response to physiological and pathological stimuli was not different in alphaMHC-mTORkd and alphaMHC-mTORca transgenic mice when compared with that of nontransgenic littermates. These findings suggest that the mTOR-mediated signaling pathway is not essential to cardiac hypertrophic growth but is involved in regulating cardiac function. Additional analysis of cardiac responses to fasting-refeeding or acute insulin administration indicated that alphaMHC-mTORkd mice had a largely impaired physiological response to nutrient energy supply and insulin stimulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326485      PMCID: PMC2376248          DOI: 10.1074/jbc.M801510200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  The TOR kinases link nutrient sensing to cell growth.

Authors:  J Rohde; J Heitman; M E Cardenas
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

2.  The conserved phosphoinositide 3-kinase pathway determines heart size in mice.

Authors:  T Shioi; P M Kang; P S Douglas; J Hampe; C M Yballe; J Lawitts; L C Cantley; S Izumo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps.

Authors:  L Wang; X Wang; C G Proud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-04       Impact factor: 4.733

4.  Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.

Authors:  Qian Yang; Ken Inoki; Tsuneo Ikenoue; Kun-Liang Guan
Journal:  Genes Dev       Date:  2006-10-15       Impact factor: 11.361

Review 5.  Ribosomal S6 kinase signaling and the control of translation.

Authors:  A Dufner; G Thomas
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

6.  Phosphatidic acid-mediated mitogenic activation of mTOR signaling.

Authors:  Y Fang; M Vilella-Bach; R Bachmann; A Flanigan; J Chen
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

7.  The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy.

Authors:  P Liao; D Georgakopoulos; A Kovacs; M Zheng; D Lerner; H Pu; J Saffitz; K Chien; R P Xiao; D A Kass; Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

8.  Mammalian TOR: a homeostatic ATP sensor.

Authors:  P B Dennis; A Jaeschke; M Saitoh; B Fowler; S C Kozma; G Thomas
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

Review 9.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

10.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Authors:  A Sekulić; C C Hudson; J L Homme; P Yin; D M Otterness; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

View more
  39 in total

1.  Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics.

Authors:  Yonghe Ding; Xiaojing Sun; Margaret Redfield; Sudhir Kushwaha; Xiaolei Xu
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

2.  MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

Authors:  Denghong Zhang; Riccardo Contu; Michael V G Latronico; Jianlin Zhang; Jian Ling Zhang; Roberto Rizzi; Daniele Catalucci; Shigeki Miyamoto; Katherine Huang; Marcello Ceci; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Kun-Liang Guan; Joan Heller Brown; Ju Chen; Nahum Sonenberg; Gianluigi Condorelli
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

3.  Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish.

Authors:  Yonghe Ding; Xiaojing Sun; Wei Huang; Tiffany Hoage; Margaret Redfield; Sudhir Kushwaha; Sridhar Sivasubbu; Xueying Lin; Stephen Ekker; Xiaolei Xu
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

Review 4.  Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.

Authors:  Lakshmi Pulakat; Vincent G DeMarco; Sivakumar Ardhanari; Anand Chockalingam; Rukhsana Gul; Adam Whaley-Connell; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

Review 5.  Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

7.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

8.  Smad7 is required for the development and function of the heart.

Authors:  Qian Chen; Hanying Chen; Dawei Zheng; Chenzhong Kuang; Hong Fang; Bingyu Zou; Wuqiang Zhu; Guixue Bu; Ting Jin; Zhenzhen Wang; Xin Zhang; Ju Chen; Loren J Field; Michael Rubart; Weinian Shou; Yan Chen
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 9.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 10.  Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies.

Authors:  Sudhir Kushwaha; Xiaolei Xu
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.